Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/34541
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- BA - IGM - Artigos de Periódicos [3687]
- IOC - Artigos de Periódicos [12776]
- PE - IAM - Artigos de Periódicos [1094]
- PR - ICC - Artigos de Periódicos [675]
Metadatos
Mostrar el registro completo del ítem
PERFORMANCE OF RECOMBINANT CHIMERIC PROTEINS IN THE SEROLOGICAL DIAGNOSIS OF TRYPANOSOMA CRUZI INFECTION IN DOGS
Proteinas quiméricas
Fatores de risco
Transmissão
Cães
Diagnóstico
Chimeric Proteins
Risk factors
Transmission
Dogs
Diagnosis
Autor
Leony, Leonardo Maia
Freitas, Natália Erdens Maron de
Del-Rei, Rodrigo Pimenta
Carneiro, Claudia Martins
Reis, Alexandre Barbosa
Jansen, Ana Maria
Xavier, Samanta Cristina das Chagas
Gomes, Yara M.
Silva, Edmilson D.
Reis, Mitermayer Galvão dos
Fraga, Deborah Bittencourt Mothé
Celedon, Paola Alejandra Fiorani
Zanchin, Nilson I. T.
Torres, Filipe Dantas
Santos, Fred Luciano Neves
Freitas, Natália Erdens Maron de
Del-Rei, Rodrigo Pimenta
Carneiro, Claudia Martins
Reis, Alexandre Barbosa
Jansen, Ana Maria
Xavier, Samanta Cristina das Chagas
Gomes, Yara M.
Silva, Edmilson D.
Reis, Mitermayer Galvão dos
Fraga, Deborah Bittencourt Mothé
Celedon, Paola Alejandra Fiorani
Zanchin, Nilson I. T.
Torres, Filipe Dantas
Santos, Fred Luciano Neves
Afiliación
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Faculty of Technology and Sciences of Bahia. Salvador, BA, Brazil.
Federal University of Ouro Preto. Nucleus of Research in Biological Sciences. Immunopathology Laboratory. Ouro Preto, MG, Brazil.
Federal University of Ouro Preto. Nucleus of Research in Biological Sciences. Immunopathology Laboratory. Ouro Preto, MG, Brazil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Immunobiological Technology Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Department of Pathology and Legal Medicine. Salvador, BA, Brazil / Yale University. School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, Connecticut, United States of America.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Molecular Biology Institute of Paraná. Curitiba, PR, Brazil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Faculty of Technology and Sciences of Bahia. Salvador, BA, Brazil.
Federal University of Ouro Preto. Nucleus of Research in Biological Sciences. Immunopathology Laboratory. Ouro Preto, MG, Brazil.
Federal University of Ouro Preto. Nucleus of Research in Biological Sciences. Immunopathology Laboratory. Ouro Preto, MG, Brazil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Immunobiological Technology Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Department of Pathology and Legal Medicine. Salvador, BA, Brazil / Yale University. School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, Connecticut, United States of America.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Molecular Biology Institute of Paraná. Curitiba, PR, Brazil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Resumen en ingles
Dogs are considered sentinels in areas of Trypanosoma cruzi transmission risk to humans. ELISA is generally the method of choice for diagnosing T. cruzi exposure in dogs, but its performance substantially depends on the antigenic matrix employed. In previous studies, our group has developed four chimeric antigens (IBMP-8.1, 8.2, 8.3, and 8.4) and evaluated their potential for diagnosing T. cruzi exposure in humans. For human sera, these chimeric antigens presented superior diagnostic performances as compared to commercial tests available in Brazil, Spain, and Argentina. Therefore, in this study we have evaluated the potential of these antigenic proteins for detection of anti-T. cruzi IgG antibodies in dog sera.
Palabras clave en portugues
Trypanosoma cruziProteinas quiméricas
Fatores de risco
Transmissão
Cães
Diagnóstico
Palabras clave en ingles
Trypanosoma cruziChimeric Proteins
Risk factors
Transmission
Dogs
Diagnosis
Compartir